SELLAS Life Sciences (SLS) Amortizatization of Intangibles (2016 - 2017)
SELLAS Life Sciences' (SLS) quarterly Amortizatization of Intangibles came in at $1000.0 in Q4 2017, down 96.3% on a QoQ basis from $27000.0 in Q3 2017.
SELLAS Life Sciences (SLS) Amortizatization of Intangibles (2016 - 2017) Analysis & Trends
SELLAS Life Sciences (SLS) has 2 years of Amortizatization of Intangibles data on file, last reported at $1000.0 in Q4 2017.
- On a quarterly basis, Amortizatization of Intangibles changed N/A year-over-year to $1000.0 in Q4 2017; TTM through Dec 2017 was $258000.0, a N/A change from a year earlier, with the FY2017 full-year figure at $258000.0, changed N/A from the prior year.
- Amortizatization of Intangibles for Q4 2017 stood at $1000.0, down from $27000.0 in the prior quarter.
- Over the last five years, Amortizatization of Intangibles for SLS reached as high as $650000.0 in Q1 2017 and fell as low as -$420000.0 in Q2 2017.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 3.22 Mn |
| 10 | SELLAS Life Sciences | 1.96 Bn | 1.96 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 1,000.00 |
| Dec 31, 2017 | 1,000.00 |
| Sep 30, 2017 | 27,000.00 |
| Sep 30, 2017 | 27,000.00 |
| Jun 30, 2017 | -420,000.00 |
| Jun 30, 2017 | -420,000.00 |
| Mar 31, 2017 | 650,000.00 |
| Mar 31, 2017 | 650,000.00 |
| Sep 30, 2016 | 568,000.00 |
| Sep 30, 2016 | 568,000.00 |
| Jun 30, 2016 | 645,000.00 |
| Jun 30, 2016 | 645,000.00 |
| Mar 31, 2016 | 67,000.00 |
| Mar 31, 2016 | 67,000.00 |